Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine

Journal of Psychopharmacology

Volumn 26, Issue 11, 2012, Pages 1417-1423

  Pringle, A ^a   Parsons, E ^a   Cowen, L G ^a   McTavish, S F ^a   Cowen, P J ^a   Harmer, C J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

anxiety; depression; emotional processing; glutamate; healthy volunteer; Memantine; NMDA receptor

Indexed keywords

MEMANTINE; PLACEBO;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EMOTIONALITY; FACIAL EXPRESSION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL TASK; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOGNITION; SINGLE DRUG DOSE; STARTLE REFLEX; TASK PERFORMANCE; VERBAL MEMORY; WORKING MEMORY;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DOUBLE-BLIND METHOD; EMOTIONS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MALE; MEMANTINE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN UPTAKE INHIBITORS; STARTLE REACTION; YOUNG ADULT;

EID: 84867489412     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112446535     Document Type: Article

References (55)

1. Anderson NH. Likableness ratings of 555 personality-trait words. J Pers Soc Psychol. 1968 ; 9: 272-279
2. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961 ; 4: 561-571
3. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 ; 47: 351-354
4. Browning M, Reid C, Cowen PJ, et al. A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol. 2007 ; 21: 684-690
5. Burghardt NS, Sullivan GM, McEwen BS, et al. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry. 2004 ; 55: 1171-1178
6. Critchley HD, Lewis PA, Orth M, et al. Vagus nerve stimulation for treatment-resistant depression: behavioral and neural effects on encoding negative material. Psychosom Med. 2007 ; 69: 17-22
7. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychol. 2006 ; 61: 741-756
8. Dix S, Gilmour G, Potts S, et al. A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. Psychopharmacology (Berl). 2010 ; 212: 227-242
9. Ekman P, Friesen WV Pictures of facial affect. Palo Alto, CA: Consulting Psychologists Press ; 1976 :
10. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007 ; 30: 136-144
11. Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009 ; 42: 81-93
12. First MB, Spitzer RL, Gibbon M, et al Structured Clinical Interview for Axis I and II DSM-IV Disorders: Patient Edition (SCID-IV/P). New York: Biometrics Research Department ; 1996 :
13. Grillon C, Levenson J, Pine DS. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology. 2007 ; 32: 225-231
14. Harmer CJ. Antidepressant drug action: a neuropsychological perspective. Depress Anxiety. 2010 ; 27: 231-233
15. Harmer CJ, Bhagwagar Z, Perrett DI, et al. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003a ; 28: 148-152
16. Harmer CJ, de Bodinat C, Dawson GR, et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. 2011 ; 25: 1159-1167
17. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009 ; 195: 102-108
18. Harmer CJ, Hill SA, Taylor MJ, et al. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry. 2003b ; 160: 990-992
19. Harmer CJ, Shelley NC, Cowen PJ, et al. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004 ; 161: 1256-1263
20. Harvey PO, Fossati P, Pochon JB, et al. Cognitive control and brain resources in major depression: an fMRI study using the n-back task. Neuroimage. 2005 ; 26: 860-869
21. Horder J, Cowen PJ, Di Simplicio M, et al. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl). 2009 ; 205: 85-91
22. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006 ; 6: 61-67
23. Karcz-Kubicha M, Jessa M, Nazar M, et al. Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology. 1997 ; 36: 1355-1367
24. Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry. 1998 ; 44: 812-824
25. Larson CL, Ruffalo D, Nietert JY, et al. Temporal stability of the emotion-modulated startle response. Psychophysiology. 2000 ; 37: 92-101
26. Malcolm CP, Cowen PJ, Harmer CJ. High-density negative ion treatment increases positive affective memory. Psychol Med. 2009 ; 39: 1930-1932
27. Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009 ; 24: 532-538
28. Minkeviciene R, Banerjee P, Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2004 ; 311: 677-682
29. Minkeviciene R, Banerjee P, Tanila H. Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology. 2008 ; 54: 1079-1085
30. Morgan CJ, Curran HV. Ketamine use: a review. Addiction. 2012 ; 107: 27-38
31. Nakaya K, Nakagawasai O, Arai Y, et al. Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors. Behav Brain Res. 2011 ; 218: 165-173
32. Nelson HE National Adult Reading Test (NART): Test Manual. Windsor, UK: NFER-Nelson ; 1982 :
33. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology. 2007 ; 53: 699-723
34. Petrakis IL, Limoncelli D, Gueorguieva R, et al. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry. 2004 ; 161: 1776-1782
35. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009 ; 65: 181-184
36. Pringle A, Browning M, Cowen PJ, et al. A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry. 2011a ; 35: 1586-1592
37. Pringle A, McTavish SF, Williams C, et al. Short-term NK1 receptor antagonism and emotional processing in healthy volunteers. Psychopharmacology (Berl). 2011b ; 215: 239-246
38. Rammsayer TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem. 2001 ; 8: 20-25
39. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 ; 348: 1333-1341
40. Reus GZ, Stringari RB, Kirsch TR, et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression?. Brain Res Bull. 2010 ; 81: 585-589
41. Rey A L'examen de clinique en psychologie. Paris: Presses Universitaires de France ; 1964 :
42. Rogoz Z, Skuza G, Maj J, et al. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002 ; 42: 1024-1030
43. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012 ; 62: 63-77
44. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008 ; 7: 426-437
45. Schugens MM, Egerter R, Daum I, et al. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci Lett. 1997 ; 224: 57-60
46. Skuza G, Rogoz Z. Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Pol J Pharmacol. 2003 ; 55: 1149-1152
47. Smith JW, Gastambide F, Gilmour G, et al. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl). 2011 ; 217: 255-269
48. Spielberger CD, Gorsuch RL, Lushene RD STAI Manual. Palo Alto, CA: Consulting Psychologists Press ; 1970 :
49. Takahashi A, Yap JJ, Bohager DZ, et al. Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 ; 204: 61-71
50. Von Zerssen D, Strain F, Schwarz D Psychological Measurements in Psychopharmacology. Pichot B, ed. Basel, Switzerland: Karger ; 1974: 189-202.
51. Watson D, Clarke LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the positive and negative affect schedule scales. J Pers Soc Psychol. 1988 ; 54: 1063-1070
52. Witt A, Macdonald N, Kirkpatrick P. Memantine hydrochloride. Nat Rev Drug Discov. 2004 ; 3: 109-110
53. Young AW, Rowland D, Calder AJ, et al. Facial expression megamix: tests of dimensional and category accounts of emotion recognition. Cognition. 1997 ; 63: 271-313
54. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006a ; 63: 856-864
55. Zarate CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006b ; 163: 153-155